Fig. 1From: High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomideExpression of IKZF1 and IKZF3 proteins in tumor cells, measured by H-score (a) and their correlation with clinical response (b). Progression free survival (PFS) and overall survival (OS) in relation to IKZF1 nuclear expression (c, d), and in relation to IKZF3 nuclear expression (e, f) detected by IHC, respectivelyBack to article page